# OnCo record nct07637513 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07637513/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07637513", "NCT07637513" ;
  schema:name "Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer"@en ;
  schema:alternateName "PrE0512"@en ;
  schema:description "A phase 3 trial of tarlatamab and durvalumab in lung cancer, run by PrECOG, LLC., not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07637513/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07637513> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/limited-stage-sclc/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:drugs <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/durvalumab/> ;
  onco:companies <https://onco.cc/companies/amgen/> .